An Update on the Biologic Effects of Fenbendazole

Carolyn Cray1, Norman H Altman2

  • 1Division of Comparative Pathology, Miller School of Medicine, University of Miami, Miami, Florida;,

Comparative Medicine
|June 28, 2022
PubMed

Insights

Fenbendazole is a common pinworm treatment for lab rodents, but it may affect research outcomes by impacting the immune system and bone marrow. Further research is exploring its potential in cancer therapy.

Area of Science:

  • Veterinary Pharmacology
  • Immunology
  • Oncology

Background:

  • Fenbendazole is the standard treatment for pinworm infections in laboratory rodents.
  • Previous reviews indicated a lack of toxicity at therapeutic doses.
  • Emerging evidence suggests potential physiological effects that could impact research findings.

Purpose of the Study:

  • To review the current understanding of fenbendazole's physiological effects in laboratory rodents.
  • To assess the potential impact of fenbendazole on research outcomes.
  • To explore emerging research into benzimidazoles, including fenbendazole, for cancer treatment.

Main Methods:

  • Literature review of studies on fenbendazole's effects in rodents.
  • Analysis of reports on physiological, reproductive, and behavioral impacts.
  • Examination of studies investigating fenbendazole in cancer models.

Main Results:

  • Fenbendazole may affect the bone marrow and immune system, despite a general lack of reported toxicity.
  • No adverse reproductive effects were noted in mice; food intake was unaffected in rats.
  • Behavioral studies are limited, with one report of subtle motor performance changes in mice.
  • Unexpected outcomes in tumor models have spurred further investigation into benzimidazoles for cancer.

Conclusions:

  • While fenbendazole is effective for pinworm infections, its physiological effects warrant consideration in research settings.
  • Further research is needed to fully elucidate fenbendazole's impact on the immune system and bone marrow.
  • The potential of benzimidazoles, including fenbendazole, in cancer therapy is an active and promising area of investigation.

Related Concept Videos

Drug Biotransformation: Overview01:16

Drug Biotransformation: Overview

Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
Drug Biotransformation: Overview01:28

Drug Biotransformation: Overview

Biotransformation, also known as drug metabolism, is a vital physiological process that chemically alters drugs, facilitating their elimination from the body and terminating their action. This process involves two main phases: phase I and phase II reactions. Phase I reactions, including oxidation, reduction, and hydrolysis, introduce or unmask polar functional groups on the drug molecule, thereby increasing its water solubility. By enhancing water solubility, the drug becomes more hydrophilic...
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Modified-Release Drug Delivery Systems: Bioavailability01:30

Modified-Release Drug Delivery Systems: Bioavailability

Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...